Press releases
- Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
- Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
- Stoke Therapeutics Announces Proposed Public Offering
- Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
- Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.50 |
---|---|
High | 10.60 |
Low | 10.50 |
Bid | 10.60 |
Offer | 11.00 |
Previous close | 10.20 |
Average volume | 0.00 |
---|---|
Shares outstanding | 52.12m |
Free float | 49.73m |
P/E (TTM) | -- |
Market cap | 602.48m USD |
EPS (TTM) | -2.38 USD |
Data delayed at least 15 minutes, as of May 02 2024 11:30 BST.
More ▼